Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jtct.2021.02.011 http://scihub22266oqcxt.onion/10.1016/j.jtct.2021.02.011 33728417!7952254!33728417     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Transplant+Cell+Ther 2021 ; 27 (5): 438.e1-438.e6 Nephropedia Template TP {{tp|p=33728417|t=2021. Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent Waves |pdf=|usr=}}{{33728417}} gab.com Text Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent Waves JO: Transplant Cell Ther http://www.kidney.de/pget.php?&tw=1&pmid=33728417 #FOAvip An evidence-based triage plan for cellular therapy distribution is critical in the face of emerging constraints on healthcare resources. We evaluated the impact of treatment delays related to COVID-19 on patients scheduled to undergo hematopoietic cell transplantation (HCT) or chimeric antigen receptor T-cell (CAR-T) therapy at our center. Data were collected in real time between March 19 and May 11, 2020, for patients who were delayed to cellular therapy. We evaluated the proportion of delayed patients who ultimately received cellular therapy, reasons for not proceeding to cellular therapy, and changes in disease and health status during delay. A total of 85 patients were delayed, including 42 patients planned for autologous HCT, 36 patients planned for allogeneic HCT, and 7 patients planned for CAR-T therapy. Fifty-six of these patients (66%) since received planned therapy. Five patients died during the delay. The most common reason for not proceeding to autologous HCT was good disease control in patients with plasma cell dyscrasias (75%). The most common reason for not proceeding to allogeneic HCT was progression of disease (42%). All patients with acute leukemia who progressed had measurable residual disease (MRD) at the time of delay, whereas no patient without MRD at the time of delay progressed. Six patients (86%) ultimately received CAR-T therapy, including 3 patients who progressed during the delay. For patients with high-risk disease such as acute leukemia, and particularly those with MRD at the time of planned HCT, treatment delay can result in devastating outcomes and should be avoided if at all possible. Twit Text FOAVip Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent Waves ????Transplant Cell Ther http://www.kidney.de/pget.php?&tw=1&pmid=33728417 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33728417 #FOAvip English Wikipedia <ref>{{Cite pmid|33728417}}</ref> Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent Waves #MMPMID33728417 Nawas MT; Shah GL; Feldman DR; Ruiz JD; Robilotti EV; Aslam AA; Dundas M; Kamboj M; Barker JN; Cho C; Chung DJ; Dahi PB; Giralt SA; Gyurkocza B; Lahoud OB; Landau HJ; Lin RJ; Mailankody S; Palomba ML; Papadopoulos EB; Politikos I; Ponce DM; Sauter CS; Shaffer BC; Scordo M; van den Brink MRM; Perales MA; Tamari R Transplant Cell Ther 2021[May]; 27 (5): 438.e1-438.e6 PMID33728417show ga An evidence-based triage plan for cellular therapy distribution is critical in the face of emerging constraints on healthcare resources. We evaluated the impact of treatment delays related to COVID-19 on patients scheduled to undergo hematopoietic cell transplantation (HCT) or chimeric antigen receptor T-cell (CAR-T) therapy at our center. Data were collected in real time between March 19 and May 11, 2020, for patients who were delayed to cellular therapy. We evaluated the proportion of delayed patients who ultimately received cellular therapy, reasons for not proceeding to cellular therapy, and changes in disease and health status during delay. A total of 85 patients were delayed, including 42 patients planned for autologous HCT, 36 patients planned for allogeneic HCT, and 7 patients planned for CAR-T therapy. Fifty-six of these patients (66%) since received planned therapy. Five patients died during the delay. The most common reason for not proceeding to autologous HCT was good disease control in patients with plasma cell dyscrasias (75%). The most common reason for not proceeding to allogeneic HCT was progression of disease (42%). All patients with acute leukemia who progressed had measurable residual disease (MRD) at the time of delay, whereas no patient without MRD at the time of delay progressed. Six patients (86%) ultimately received CAR-T therapy, including 3 patients who progressed during the delay. For patients with high-risk disease such as acute leukemia, and particularly those with MRD at the time of planned HCT, treatment delay can result in devastating outcomes and should be avoided if at all possible. |*COVID-19/complications/epidemiology/transmission[MESH] |*Hematopoietic Stem Cell Transplantation/statistics & numerical data[MESH] |*Immunotherapy, Adoptive[MESH] |*Pandemics[MESH] |*SARS-CoV-2[MESH] |*Time-to-Treatment/statistics & numerical data[MESH] |Adult[MESH] |Aged[MESH] |Allografts[MESH] |Amyloidosis/therapy[MESH] |Anemia, Aplastic/therapy[MESH] |Civil Defense[MESH] |Cross Infection/epidemiology/prevention & control[MESH] |Disease Progression[MESH] |Evidence-Based Practice/organization & administration[MESH] |Female[MESH] |Humans[MESH] |Infection Control/methods[MESH] |Infectious Disease Transmission, Professional-to-Patient[MESH] |Leukemia/mortality/pathology/therapy[MESH] |Male[MESH] |Middle Aged[MESH] |Myelodysplastic-Myeloproliferative Diseases/mortality/therapy[MESH] |Neoplasm, Residual[MESH] |Neoplasms/mortality/therapy[MESH] |New York City/epidemiology[MESH] |Resource Allocation[MESH] |Transplantation, Autologous[MESH] |Triage/organization & administration[MESH]Cellular Therapy During COVID-19: Lessons Learned and Preparing for Su(epmc).pdf DeepDyve Pubget Overpricing